BAcKGROUND The individual performances and the complementarity of crohn's disease(cD)activity index(cDAI), c-reactive protein(cRP) and faecal calprotectin(Fcal) to monitor patients with cD remain poorly inves-tigated ...
详细信息
BAcKGROUND The individual performances and the complementarity of crohn's disease(cD)activity index(cDAI), c-reactive protein(cRP) and faecal calprotectin(Fcal) to monitor patients with cD remain poorly inves-tigated in the era of "tight control"and "treat to target" *** To assess cDAI, cRP and Fcal variation, alone or combined, after 12 wk(W12) of anti-tumor necrosis factor(TNF) therapy to predict corticosteroids-free remission(cFREM = cDAI cRP cal c intensification and no surgery) at *** cD adult patients needing anti-TNF therapy with cDAI > 150 and either cRP >2.9 mg/L or Fcal > 250 μg/g were prospectively *** Among the 40 included patients, 13 patients(32.5%) achieved cFREM at W52. In univariable analysis, cDAI cRP level cal improvement at W12(Fcal cal crease of Fcal or normalization of Fcal(ctive of cFREM at W52. combined endpoint(cDAI cRP ≤ 2.9 mg/L and Fcal improvement) at W12 was the best predictor of cFREM at W52 with positive predictive value = 100.0%(100.0-100.0)and negative predictive value = 87.1%(75.3-98.9). In multivariable analysis, Fcal improvement at W12 [odd ratio(OR) = 45.1(2.96-687.9); P = 0.03] was a better predictor of cFREM at W52 than cDAI cRP cONcLUSION The combined monitoring of cDAI, cRP and Fcal after anti-TNF induction therapy is able to predict favorable outcome within one year in patients with cD.
暂无评论